191 related articles for article (PubMed ID: 29334492)
1. Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3α-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons.
Gordy JT; Luo K; Francica B; Drake C; Markham RB
J Immunother; 2018 May; 41(4):181-189. PubMed ID: 29334492
[TBL] [Abstract][Full Text] [Related]
2. Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model.
Gordy JT; Luo K; Zhang H; Biragyn A; Markham RB
J Immunother Cancer; 2016; 4():96. PubMed ID: 28018602
[TBL] [Abstract][Full Text] [Related]
3. Treatment with an immature dendritic cell-targeting vaccine supplemented with IFN-α and an inhibitor of DNA methylation markedly enhances survival in a murine melanoma model.
Gordy JT; Luo K; Kapoor A; Kim ES; Ayeh SK; Karakousis PC; Markham RB
Cancer Immunol Immunother; 2020 Apr; 69(4):569-580. PubMed ID: 31980915
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two routes of administration of a cationic liposome formulation for a prophylactic DC vaccination in a murine melanoma model.
Yazdani M; Nikpoor AR; Gholizadeh Z; Mohamadian Roshan N; Seifalian A; Jaafari MR; Badiee A
Int Immunopharmacol; 2021 Sep; 98():107833. PubMed ID: 34352472
[TBL] [Abstract][Full Text] [Related]
5. A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model.
Gupta S; Termini JM; Rivas Y; Otero M; Raffa FN; Bhat V; Farooq A; Stone GW
Vaccine; 2015 Sep; 33(38):4798-806. PubMed ID: 26241951
[TBL] [Abstract][Full Text] [Related]
6. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
7. IFNα and 5-Aza-2'-deoxycytidine combined with a dendritic-cell targeting DNA vaccine alter tumor immune cell infiltration in the B16F10 melanoma model.
Gordy JT; Sandhu AK; Fessler K; Luo K; Kapoor AR; Ayeh SK; Hui Y; Schill C; Chen F; Wang T; Karanika S; Sunshine JC; Karakousis PC; Markham RB
Front Immunol; 2022; 13():1074644. PubMed ID: 36741387
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of cancer vaccine settings for the selection of an effective protocol in mice.
Kalli F; Machiorlatti R; Battaglia F; Parodi A; Conteduca G; Ferrera F; Proietti M; Tardito S; Sanguineti M; Millo E; Fenoglio D; De Palma R; Inghirami G; Filaci G
J Transl Med; 2013 May; 11():120. PubMed ID: 23663506
[TBL] [Abstract][Full Text] [Related]
9. CD204 suppresses large heat shock protein-facilitated priming of tumor antigen gp100-specific T cells and chaperone vaccine activity against mouse melanoma.
Qian J; Yi H; Guo C; Yu X; Zuo D; Chen X; Kane JM; Repasky EA; Subjeck JR; Wang XY
J Immunol; 2011 Sep; 187(6):2905-14. PubMed ID: 21832164
[TBL] [Abstract][Full Text] [Related]
10. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.
Hailemichael Y; Woods A; Fu T; He Q; Nielsen MC; Hasan F; Roszik J; Xiao Z; Vianden C; Khong H; Singh M; Sharma M; Faak F; Moore D; Dai Z; Anthony SM; Schluns KS; Sharma P; Engelhard VH; Overwijk WW
J Clin Invest; 2018 Apr; 128(4):1338-1354. PubMed ID: 29480817
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with dendritic cells pulsed ex vivo with gp100 peptide-decorated liposomes enhances the efficacy of anti PD-1 therapy in a mouse model of melanoma.
Yazdani M; Gholizadeh Z; Nikpoor AR; Hatamipour M; Alani B; Nikzad H; Mohamadian Roshan N; Verdi J; Jaafari MR; Noureddini M; Badiee A
Vaccine; 2020 Jul; 38(35):5665-5677. PubMed ID: 32653275
[TBL] [Abstract][Full Text] [Related]
12. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy.
Llopiz D; Ruiz M; Silva L; Repáraz D; Aparicio B; Egea J; Lasarte JJ; Redin E; Calvo A; Angel M; Berzofsky JA; Stroncek D; Sarobe P
Cancer Lett; 2021 Feb; 499():279-289. PubMed ID: 33232788
[TBL] [Abstract][Full Text] [Related]
14. Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18.
Yamanaka R; Xanthopoulos KG
DNA Cell Biol; 2005 May; 24(5):317-24. PubMed ID: 15869409
[TBL] [Abstract][Full Text] [Related]
15. CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine.
Leitch J; Fraser K; Lane C; Putzu K; Adema GJ; Zhang QJ; Jefferies WA; Bramson JL; Wan Y
J Immunol; 2004 May; 172(9):5200-5. PubMed ID: 15100257
[TBL] [Abstract][Full Text] [Related]
16. IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination.
Llopiz D; Ruiz M; Infante S; Villanueva L; Silva L; Hervas-Stubbs S; Alignani D; Guruceaga E; Lasarte JJ; Sarobe P
Oncotarget; 2017 Jan; 8(2):2659-2671. PubMed ID: 27926522
[TBL] [Abstract][Full Text] [Related]
17. Syngeneic murine model for prostate cancer using RM1 cells transfected with gp100.
Yeon A; Wang Y; Su S; Lo EM; Kim HL
Prostate; 2020 Apr; 80(5):424-431. PubMed ID: 32017163
[TBL] [Abstract][Full Text] [Related]
18. Analysis of antitumor activity elicited by vaccination with combinations of interleukin-12 DNA with gp100 DNA or the chemokine CCL21 in vivo.
Elzaouk L; Pavlovic J; Moelling K
Hum Gene Ther; 2006 Aug; 17(8):859-70. PubMed ID: 16942445
[TBL] [Abstract][Full Text] [Related]
19. CD4 T cell dependent tumor immunity stimulated by dendritic cell based vaccine.
Zhang S; Li W; Xia Z; Mao Y
Biochem Biophys Res Commun; 2011 Sep; 413(2):294-8. PubMed ID: 21893031
[TBL] [Abstract][Full Text] [Related]
20. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
